Adverse reactions to vaccines practice parameter 2012 update

John M. Kelso, Matthew J. Greenhawt, James T. Li, Richard A. Nicklas, David I. Bernstein, Joann Blessing-Moore, Linda Cox, David Khan, David M. Lang, John Oppenheimer, Jay M. Portnoy, Christopher R. Randolph, Diane E. Schuller, Sheldon L. Spector, Stephen A. Tilles, Dana Wallace

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Mild local reactions and fever after vaccinations are common and do not contraindicate future doses. Anaphylactic reactions to vaccines are rare and should be evaluated with skin tests to the vaccine and its components. If the skin test results are negative, subsequent doses can be administered in the usual manner but under observation. If the skin test results are positive and the patient requires subsequent doses, the vaccine can be administered in graded doses under observation. Some nonanaphylactic reactions to vaccines might also require evaluation, but only a few are contraindications to future doses. Pregnant women and persons who are immune compromised should generally not receive live vaccines. Purported long-term sequelae of vaccination, such as autism, are not supported by epidemiologic studies. Patients with egg allergy of any severity should receive annual influenza vaccinations because studies have demonstrated a very low rate of reactions. Studies to date have evaluated the injectable trivalent nfluenza vaccine (TIV), and thus TIV, rather than the live attenuated influenza vaccine (LAIV), should be used for recipients with egg allergy. All influenza vaccines available in the United States contain low amounts of ovalbumin. Neither skin testing with the vaccine nor dividing the dose is required; however, the vaccine should be administered in a setting in which anaphylaxis can be recognized and treated.

Original languageEnglish (US)
Pages (from-to)25-43
Number of pages19
JournalJournal of Allergy and Clinical Immunology
Volume130
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Vaccines
Egg Hypersensitivity
Skin Tests
Attenuated Vaccines
Vaccination
Influenza Vaccines
Anaphylaxis
Observation
Ovalbumin
Autistic Disorder
Human Influenza
Pregnant Women
Epidemiologic Studies
Fever
Skin
Injections

Keywords

  • adverse reaction
  • allergy
  • egg allergy
  • immunization
  • influenza vaccine
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Kelso, J. M., Greenhawt, M. J., Li, J. T., Nicklas, R. A., Bernstein, D. I., Blessing-Moore, J., ... Wallace, D. (2012). Adverse reactions to vaccines practice parameter 2012 update. Journal of Allergy and Clinical Immunology, 130(1), 25-43. https://doi.org/10.1016/j.jaci.2012.04.003

Adverse reactions to vaccines practice parameter 2012 update. / Kelso, John M.; Greenhawt, Matthew J.; Li, James T.; Nicklas, Richard A.; Bernstein, David I.; Blessing-Moore, Joann; Cox, Linda; Khan, David; Lang, David M.; Oppenheimer, John; Portnoy, Jay M.; Randolph, Christopher R.; Schuller, Diane E.; Spector, Sheldon L.; Tilles, Stephen A.; Wallace, Dana.

In: Journal of Allergy and Clinical Immunology, Vol. 130, No. 1, 07.2012, p. 25-43.

Research output: Contribution to journalArticle

Kelso, JM, Greenhawt, MJ, Li, JT, Nicklas, RA, Bernstein, DI, Blessing-Moore, J, Cox, L, Khan, D, Lang, DM, Oppenheimer, J, Portnoy, JM, Randolph, CR, Schuller, DE, Spector, SL, Tilles, SA & Wallace, D 2012, 'Adverse reactions to vaccines practice parameter 2012 update', Journal of Allergy and Clinical Immunology, vol. 130, no. 1, pp. 25-43. https://doi.org/10.1016/j.jaci.2012.04.003
Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J et al. Adverse reactions to vaccines practice parameter 2012 update. Journal of Allergy and Clinical Immunology. 2012 Jul;130(1):25-43. https://doi.org/10.1016/j.jaci.2012.04.003
Kelso, John M. ; Greenhawt, Matthew J. ; Li, James T. ; Nicklas, Richard A. ; Bernstein, David I. ; Blessing-Moore, Joann ; Cox, Linda ; Khan, David ; Lang, David M. ; Oppenheimer, John ; Portnoy, Jay M. ; Randolph, Christopher R. ; Schuller, Diane E. ; Spector, Sheldon L. ; Tilles, Stephen A. ; Wallace, Dana. / Adverse reactions to vaccines practice parameter 2012 update. In: Journal of Allergy and Clinical Immunology. 2012 ; Vol. 130, No. 1. pp. 25-43.
@article{a0c3942a2afb427dae72aab5d1098198,
title = "Adverse reactions to vaccines practice parameter 2012 update",
abstract = "Mild local reactions and fever after vaccinations are common and do not contraindicate future doses. Anaphylactic reactions to vaccines are rare and should be evaluated with skin tests to the vaccine and its components. If the skin test results are negative, subsequent doses can be administered in the usual manner but under observation. If the skin test results are positive and the patient requires subsequent doses, the vaccine can be administered in graded doses under observation. Some nonanaphylactic reactions to vaccines might also require evaluation, but only a few are contraindications to future doses. Pregnant women and persons who are immune compromised should generally not receive live vaccines. Purported long-term sequelae of vaccination, such as autism, are not supported by epidemiologic studies. Patients with egg allergy of any severity should receive annual influenza vaccinations because studies have demonstrated a very low rate of reactions. Studies to date have evaluated the injectable trivalent nfluenza vaccine (TIV), and thus TIV, rather than the live attenuated influenza vaccine (LAIV), should be used for recipients with egg allergy. All influenza vaccines available in the United States contain low amounts of ovalbumin. Neither skin testing with the vaccine nor dividing the dose is required; however, the vaccine should be administered in a setting in which anaphylaxis can be recognized and treated.",
keywords = "adverse reaction, allergy, egg allergy, immunization, influenza vaccine, Vaccine",
author = "Kelso, {John M.} and Greenhawt, {Matthew J.} and Li, {James T.} and Nicklas, {Richard A.} and Bernstein, {David I.} and Joann Blessing-Moore and Linda Cox and David Khan and Lang, {David M.} and John Oppenheimer and Portnoy, {Jay M.} and Randolph, {Christopher R.} and Schuller, {Diane E.} and Spector, {Sheldon L.} and Tilles, {Stephen A.} and Dana Wallace",
year = "2012",
month = "7",
doi = "10.1016/j.jaci.2012.04.003",
language = "English (US)",
volume = "130",
pages = "25--43",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Adverse reactions to vaccines practice parameter 2012 update

AU - Kelso, John M.

AU - Greenhawt, Matthew J.

AU - Li, James T.

AU - Nicklas, Richard A.

AU - Bernstein, David I.

AU - Blessing-Moore, Joann

AU - Cox, Linda

AU - Khan, David

AU - Lang, David M.

AU - Oppenheimer, John

AU - Portnoy, Jay M.

AU - Randolph, Christopher R.

AU - Schuller, Diane E.

AU - Spector, Sheldon L.

AU - Tilles, Stephen A.

AU - Wallace, Dana

PY - 2012/7

Y1 - 2012/7

N2 - Mild local reactions and fever after vaccinations are common and do not contraindicate future doses. Anaphylactic reactions to vaccines are rare and should be evaluated with skin tests to the vaccine and its components. If the skin test results are negative, subsequent doses can be administered in the usual manner but under observation. If the skin test results are positive and the patient requires subsequent doses, the vaccine can be administered in graded doses under observation. Some nonanaphylactic reactions to vaccines might also require evaluation, but only a few are contraindications to future doses. Pregnant women and persons who are immune compromised should generally not receive live vaccines. Purported long-term sequelae of vaccination, such as autism, are not supported by epidemiologic studies. Patients with egg allergy of any severity should receive annual influenza vaccinations because studies have demonstrated a very low rate of reactions. Studies to date have evaluated the injectable trivalent nfluenza vaccine (TIV), and thus TIV, rather than the live attenuated influenza vaccine (LAIV), should be used for recipients with egg allergy. All influenza vaccines available in the United States contain low amounts of ovalbumin. Neither skin testing with the vaccine nor dividing the dose is required; however, the vaccine should be administered in a setting in which anaphylaxis can be recognized and treated.

AB - Mild local reactions and fever after vaccinations are common and do not contraindicate future doses. Anaphylactic reactions to vaccines are rare and should be evaluated with skin tests to the vaccine and its components. If the skin test results are negative, subsequent doses can be administered in the usual manner but under observation. If the skin test results are positive and the patient requires subsequent doses, the vaccine can be administered in graded doses under observation. Some nonanaphylactic reactions to vaccines might also require evaluation, but only a few are contraindications to future doses. Pregnant women and persons who are immune compromised should generally not receive live vaccines. Purported long-term sequelae of vaccination, such as autism, are not supported by epidemiologic studies. Patients with egg allergy of any severity should receive annual influenza vaccinations because studies have demonstrated a very low rate of reactions. Studies to date have evaluated the injectable trivalent nfluenza vaccine (TIV), and thus TIV, rather than the live attenuated influenza vaccine (LAIV), should be used for recipients with egg allergy. All influenza vaccines available in the United States contain low amounts of ovalbumin. Neither skin testing with the vaccine nor dividing the dose is required; however, the vaccine should be administered in a setting in which anaphylaxis can be recognized and treated.

KW - adverse reaction

KW - allergy

KW - egg allergy

KW - immunization

KW - influenza vaccine

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84862886526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862886526&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2012.04.003

DO - 10.1016/j.jaci.2012.04.003

M3 - Article

C2 - 22608573

AN - SCOPUS:84862886526

VL - 130

SP - 25

EP - 43

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -